There is a growing need to address the lack of regular exercise among Hong Kong students. Turning back the clock to more physically active childhoods is not an option. Without action at home and school to maintain physical activity amid a digital lifestyle, today’s schoolchildren face a greater risk – and an earlier onset – of ill health. A government report for the 2024-25 school year says about ...
There is a growing need to address the lack of regular exercise among Hong Kong students. Turning back the clock to more physically active childhoods is not an option. Without action at home and school to maintain physical activity amid a digital lifestyle, today’s schoolchildren face a greater risk – and an earlier onset – of ill health. A government report for the 2024-25 school year says about 94 per cent of students do not get enough moderate to vigorous exercise, recommended for at least an...
Shares of the Fundrise Innovation Fund fell sharply for a second straight day Friday, though remain well above the underlying value of its holdings in private tech firms including the potentially IPO-bound SpaceX and Anthropic PBC.
Shares of the Fundrise Innovation Fund fell sharply for a second straight day Friday, though remain well above the underlying value of its holdings in private tech firms including the potentially IPO-bound SpaceX and Anthropic PBC.
Storied IT research specialist Gartner (NYSE: IT) ended the week on a down note, with its share price declining by nearly 1% on Friday. A bearish analyst note prompted investors to reconsider whether to own the stock, and more than a few sold it as they headed into the weekend. That morning Wells Fargo 's Jason Haas cut his price target on Gartner to $140 per share from his previous $150. He maint...
Storied IT research specialist Gartner (NYSE: IT) ended the week on a down note, with its share price declining by nearly 1% on Friday. A bearish analyst note prompted investors to reconsider whether to own the stock, and more than a few sold it as they headed into the weekend. That morning Wells Fargo 's Jason Haas cut his price target on Gartner to $140 per share from his previous $150. He maintained his underweight (sell, in other words) recommendation as he did so. Image source: Getty Images. Continue reading
Dragon Claws/iStock via Getty Images Investment Thesis The NEOS MLP & Energy Infrastructure High Income ETF ( MLPI ) caught my attention immediately when the new product from the NEOS team was launched. Also, after looking at and comparing similar funds investing in midstream assets, which readers often recommended I pay special attention to, MLPI stood out. The lack of a track record, though, kep...
Dragon Claws/iStock via Getty Images Investment Thesis The NEOS MLP & Energy Infrastructure High Income ETF ( MLPI ) caught my attention immediately when the new product from the NEOS team was launched. Also, after looking at and comparing similar funds investing in midstream assets, which readers often recommended I pay special attention to, MLPI stood out. The lack of a track record, though, kept me from taking a practical interest in this asset. Since we now have the first results after three months, which allow us to assess MLPI’s performance, here’s my attempt to compare it with the sector’s benchmark—the Alerian MLP ETF ( AMLP ). Midstream assets have proven to be more volatile over this short period, which is primarily due to rising energy prices. Since we are currently in a bull market, we can immediately find an answer to the question regarding whether NEOS funds are subject to a "growth ceiling." Comparing the total returns of the MLPI and the AMLP over a 3-month period shows that the former outperformed the latter by 4.36%. Therefore, in practice, these theoretical disadvantages are offset by the effective actions of NEOS portfolio managers. The comparison of MLPI and AMLP in this article confirms that the former fund deserves the status of "top performer" among MLP and Midstream assets. Fundamental Similarities Between MLPI and AMLP Every investor should understand the actual structure of these investment vehicles, as although MLPI and AMLP are two popular ETFs that invest in MLP assets, their internal workings differ significantly. Nevertheless, it is worth noting their common "genetic code" first. Firstly, the two funds are pure-play MLP holdings in the midstream sector. Because of this, the structure is classified as a C-Corporation. Secondly, the funds' assets do not include any companies in the E&P sector. Therefore, there is 67% overlap in their holdings. As a result, the price movements of their shares are highly correlated. Thirdly, investors who...
Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals (NASDAQ:SUPN) , reported the direct sale of 107,250 shares of Common Stock over March 16–18, 2026, via open-market transactions, for a transaction value of approximately $5.4 million, according to the SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($50.24); post-transaction value based o...
Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals (NASDAQ:SUPN) , reported the direct sale of 107,250 shares of Common Stock over March 16–18, 2026, via open-market transactions, for a transaction value of approximately $5.4 million, according to the SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($50.24); post-transaction value based on March 18, 2026 market close ($50.24). * 1-year performance calculated using March 18th, 2026 as the reference date. Continue reading
Liubomyr Vorona/iStock via Getty Images Lenz Therapeutics ( LENZ ) is an early-stage biotechnology company based in Solana Beach, CA. Its main product is VIZZ (aceclidine ophthalmic solution) 1.44%, marketed as ‘the first and only aceclidine-based eye drop for the treatment of presbyopia’. The word presbyopia has ancient Greek roots, literally meaning “old man’s eye”. It is a condition where, as w...
Liubomyr Vorona/iStock via Getty Images Lenz Therapeutics ( LENZ ) is an early-stage biotechnology company based in Solana Beach, CA. Its main product is VIZZ (aceclidine ophthalmic solution) 1.44%, marketed as ‘the first and only aceclidine-based eye drop for the treatment of presbyopia’. The word presbyopia has ancient Greek roots, literally meaning “old man’s eye”. It is a condition where, as we age, our near-sighted vision worsens. While not everyone is diagnosed with the condition, it is considered to affect almost everyone as they age, with most people developing symptoms in their 40s or 50s. It is not a disease, but instead a natural, progressive age-related process whereby the eye loses its ability to focus on nearby objects due to a loss of flexibility and elasticity in the crystalline lens. It is why reading becomes more challenging as we age, particularly in low light. Ellis Eye The standard treatments for presbyopia are glasses, bifocals, or contact lenses. Collectively, this is an enormous global market; Fortune Business Insights estimates it as more than $180 billion . It is also worth noting that traditional LASIK surgery done on both eyes is not intended to fix presbyopia , as the technique is for fixing far-sighted vision. However, options like monovision /multifocal ablation which use lasers to set one eye for near vision and the other for far vision can fix the symptoms temporarily. I say temporarily because, again, presbyopia is age-related and progressive so, as years pass post-surgery, patients will likely require reading glasses anyway. Estimates suggest 1.8 billion people globally have presbyopia – or 128 million Americans – but almost everyone beyond a certain age develops the condition even if they never realize it or get an official diagnosis. In any event, what is certain is that the condition is extremely common among adults in their middle/late stage of life. Vizz received FDA approval in July 2025 as an eye-drop formula that can be use...
PM Images/DigitalVision via Getty Images Introduction The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts. However, since this list is only produced once per month, the data in it can quickly get out of date. Furthermore, with around 700 companies on the list, the sheer amount of data can quickly become overwhelming. In ...
PM Images/DigitalVision via Getty Images Introduction The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts. However, since this list is only produced once per month, the data in it can quickly get out of date. Furthermore, with around 700 companies on the list, the sheer amount of data can quickly become overwhelming. In this weekly series, I highlight recent and upcoming dividend related activity for dividend stocks on the Dividend Champions list. In the data presented below, Yield is forward annualized and Years reflects the up-to-date streak, including dividends declared since the last edition of the Dividend Champions list. Dividend Changes In the past week, the following companies declared dividends which changed from their previous payouts. Increases: Company Symbol Ex-Div Pay Old Rate New Rate Increase Yield Years BankUnited, Inc. ( BKU ) 4/10 4/30 0.31 0.33 6.45% 2.97% 7 Oxford Industries, Inc. ( OXM ) 4/17 5/1 0.69 0.7 1.45% 8.08% 6 Click to enlarge Decreases: None Last Chance to Buy These dividend growth stocks have ex-dividend dates approaching. The following tables indicate the last day you can buy these stocks in order to be eligible for the upcoming dividend. Tables are sorted alphabetically by symbol. Monday Mar 30 (Ex-Div 3/31) Company Symbol Pay Date Payout Price Yield Years Agilent Technologies, Inc. ( A ) 4/22 0.255 110.24 0.93% 15 Agree Realty Corporation ( ADC ) 4/15 0.262 74.41 4.23% 13 BancFirst Corporation ( BANF ) 4/15 0.49 106.72 1.84% 32 Franklin Resources, Inc. ( BEN ) 4/10 0.33 22.75 5.80% 46 Broadstone Net Lease, Inc. ( BNL ) 4/15 0.2925 18.46 6.34% 7 Camden Property Trust ( CPT ) 4/17 1.06 96.96 4.37% 16 CareTrust REIT, Inc. ( CTRE ) 4/15 0.39 37.13 4.20% 13 Dillard's, Inc. ( DDS ) 5/4 0.3 555.01 0.22% 15 Amdocs Limited ( DOX ) 4/24 0.569 64.32 3.54% 15 EastGroup Properties, Inc. ( EGP ) 4/15 1.55 183.17 3.38% 14 The Ensign Group, Inc. ( ENSG ) 4/30 0.065 200....
Chair says ‘staff are hurting’ after ‘difficult week’ Reform UK leader visited club on Monday The Ipswich Town chair and chief executive Mark Ashton has apologised for the club’s handling of Nigel Farage’s visit to Portman Road this week. Farage visited the club on Monday, with footage of his trip – including images of the Reform UK leader holding up an Ipswich No 10 shirt with his name on the bac...
Chair says ‘staff are hurting’ after ‘difficult week’ Reform UK leader visited club on Monday The Ipswich Town chair and chief executive Mark Ashton has apologised for the club’s handling of Nigel Farage’s visit to Portman Road this week. Farage visited the club on Monday, with footage of his trip – including images of the Reform UK leader holding up an Ipswich No 10 shirt with his name on the back – being used by the political party on social media. More details to follow Continue reading...
Something unusual is happening in the software sector. And investors are starting to notice. Jim Cramer is flagging an unexpected laggard: Microsoft (MSFT). Despite its dominance as the world’s largest software company by revenue and a leader in cloud and artificial intelligence, the stock has ...
Something unusual is happening in the software sector. And investors are starting to notice. Jim Cramer is flagging an unexpected laggard: Microsoft (MSFT). Despite its dominance as the world’s largest software company by revenue and a leader in cloud and artificial intelligence, the stock has ...
watch now VIDEO 4:33 04:33 It was another week when it paid to get out of anything in tech that used to be good: Jim Cramer Mad Money with Jim Cramer CNBC's Jim Cramer outlined his game plan for the week ahead, warning that a relentless rise in oil tied to the Iran war is continuing to pressure stocks – and could signal more downside. "Another miserable week. Four weeks since the war started and i...
watch now VIDEO 4:33 04:33 It was another week when it paid to get out of anything in tech that used to be good: Jim Cramer Mad Money with Jim Cramer CNBC's Jim Cramer outlined his game plan for the week ahead, warning that a relentless rise in oil tied to the Iran war is continuing to pressure stocks – and could signal more downside. "Another miserable week. Four weeks since the war started and it's been pretty darn awful," Cramer said Friday on "Mad Money," adding that "the history of oil shocks is littered with bear markets, 20% drawdowns that say raise cash." Stocks finished lower Friday led by the Nasdaq down 2.15%, the Dow Jones Industrial Average dropping 1.73% and the S&P 500 falling 1.67%, logging its fifth straight weekly decline. With the conflict difficult to predict, Cramer said one trade has consistently done well. "Right now, the one thing that's been consistently right is to buy oil stocks. Every time they're down. Every time they're up. It just doesn't matter, because crude is headed higher." That dynamic has fueled a rotation out of tech stocks. "They're all bad now, including the once loved, now disliked Nvidia ," he said, noting investors now favor "they don't mind the soda stocks, any pharma stock, and I gotta tell ya they like the oil drillers. Tech, nothing." Here's what Cramer will be watching next week: Monday Markets will likely remain driven by developments in the Iran war. With the Strait of Hormuz, a critical oil passageway, still constrained, and tensions between the U.S. and Iran still high, it's likely that oil goes higher and therefore, stocks go lower. Tuesday McCormick & Company reports with a potential catalyst tied to talks to acquire Unilever 's food brands. "I love this combo. I hope it works out," Cramer said. After the close Nike reports. "There's no line of sight for Nike to return to greatness," he said, citing challenges in the China market, along with competition and inventory issues. Investors will also get the monthly J...
Javier Milei, Argentina's president, at Bloomberg House during the World Economic Forum (WEF) in Davos, Switzerland, on Thursday, Jan. 22, 2026. The annual Davos gathering of political leaders, top executives and celebrities runs from Jan. 19-23.
Javier Milei, Argentina's president, at Bloomberg House during the World Economic Forum (WEF) in Davos, Switzerland, on Thursday, Jan. 22, 2026. The annual Davos gathering of political leaders, top executives and celebrities runs from Jan. 19-23.
Thomas Rowland, an executive at ANI Pharmaceuticals (NASDAQ:ANIP) , reported the sale of 4,772 shares of common stock in an open-market transaction on March 11, 2026, according to a SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($74.91). * 1-year performance calculated using Friday’s closing prices. Continue reading
Thomas Rowland, an executive at ANI Pharmaceuticals (NASDAQ:ANIP) , reported the sale of 4,772 shares of common stock in an open-market transaction on March 11, 2026, according to a SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($74.91). * 1-year performance calculated using Friday’s closing prices. Continue reading